# Marguerite Hutchinson

> Marguerite Hutchinson, J.D., is the Chief Business Officer of STORM Therapeutics, a Cambridge, UK clinical-stage biotech advancing the first RNA methyltransferase inhibitor into clinical development. A Harvard graduate and lawyer by training, she has spent more than a decade turning early science into deals - building licensing partnerships with Roche, Merck, AstraZeneca, AbbVie and Cancer Research UK, founding and funding a UCSF spin-out, and steering a first-in-class cancer drug through to approval. She was named one of the Top 25 Women Leaders in Biotechnology.

- **Role:** Chief Business Officer at STORM Therapeutics
- **Organizations:** STORM Therapeutics, Tatara Therapeutics, Frontier Medicines Corporation, Plexxikon Inc. (Daiichi Sankyo Group), University of California, San Francisco (UCSF)
- **Nationality:** American
- **Education:** B.A. (Government), Harvard University, J.D., University of San Diego School of Law
- **Known for:** Named one of the Top 25 Women Leaders in Biotechnology (Healthcare Technology Report, 2021), Helped advance and gain approval of TURALIO (pexidartinib), a first-in-class drug for tenosynovial giant cell tumor, Out-licensed bezuclastinib to Cogent Biosciences and plixorafenib to Fore Biotherapeutics, securing upfront, milestone and royalty payments

## Career timeline

- **2013** — Joined Plexxikon Inc. in business development and legal roles; rose to Chief Operating Officer and General Counsel
- **2019** — Contributed to Phase 3 development and approval of TURALIO (pexidartinib), a first-in-class therapy for tenosynovial giant cell tumor
- **2021** — Led Plexxikon to a jury verdict in the Plexxikon v. Novartis patent infringement case; named one of the Top 25 Women Leaders in Biotechnology
- **2021** — Appointed Chief Business Officer at Frontier Medicines Corporation, leading business development including an AbbVie collaboration
- **2022** — Founded Tatara Therapeutics, a UCSF spin-out, as Chief Executive Officer and raised seed financing
- **2023** — Appointed Chief Business Officer of STORM Therapeutics (effective November 1, 2023)

## Achievements

- Named one of the Top 25 Women Leaders in Biotechnology (Healthcare Technology Report, 2021)
- Helped advance and gain approval of TURALIO (pexidartinib), a first-in-class drug for tenosynovial giant cell tumor
- Out-licensed bezuclastinib to Cogent Biosciences and plixorafenib to Fore Biotherapeutics, securing upfront, milestone and royalty payments
- Established and managed collaborations with Roche, Merck, AstraZeneca, Array and Cancer Research UK at Plexxikon
- Won the Plexxikon v. Novartis patent infringement case (jury verdict, July 2021)
- Oversaw construction of a 50,000-square-foot, $15M lab and office space
- Founded and raised seed financing for Tatara Therapeutics, a UCSF spin-out

## Latest updates

- **2023-11** — Appointed Chief Business Officer of STORM Therapeutics, joining as the company advances the first RNA methyltransferase inhibitor into clinical development.

## Links

- Website: https://stormtherapeutics.com
- LinkedIn: http://www.linkedin.com/in/marguerite-hutchinson-29b23b28

---

Profile page: https://yespress.io/marguerite-hutchinson
Published by YesPress — https://yespress.io
Last updated: 2026-06-11